CU20120086A7 - Nuevos co-cristales de agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen - Google Patents

Nuevos co-cristales de agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen

Info

Publication number
CU20120086A7
CU20120086A7 CU2012000086A CU20120086A CU20120086A7 CU 20120086 A7 CU20120086 A7 CU 20120086A7 CU 2012000086 A CU2012000086 A CU 2012000086A CU 20120086 A CU20120086 A CU 20120086A CU 20120086 A7 CU20120086 A7 CU 20120086A7
Authority
CU
Cuba
Prior art keywords
crystals
pharmaceutical compositions
compositions containing
preparation procedure
agomelatine
Prior art date
Application number
CU2012000086A
Other languages
English (en)
Inventor
Philippe Letellier
Michael Lynch
Jean-Manuel Pean
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of CU20120086A7 publication Critical patent/CU20120086A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Anesthesiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Nuevo co-cristal de agomelatina constituido: - por agomelatina o N-[2-(7-metoxi-1-naftil)etil]acetamida de fórmula (I) y - por un ácido orgánico Medicamentos
CU2012000086A 2011-06-09 2012-05-31 Nuevos co-cristales de agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen CU20120086A7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1101766A FR2976284B1 (fr) 2011-06-09 2011-06-09 Nouveaux co-cristaux d'agomelatine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Publications (1)

Publication Number Publication Date
CU20120086A7 true CU20120086A7 (es) 2014-01-29

Family

ID=46690337

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000086A CU20120086A7 (es) 2011-06-09 2012-05-31 Nuevos co-cristales de agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen

Country Status (5)

Country Link
CN (1) CN102816079B (es)
AP (1) AP3198A (es)
CU (1) CU20120086A7 (es)
FR (1) FR2976284B1 (es)
UA (1) UA112407C2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE036989T2 (hu) * 2013-06-06 2018-08-28 Zentiva Ks Agomelatin készítmény, amely agomelatint ko-kristály formájában tartalmaz
EP2810647A1 (en) * 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
ES2959460T3 (es) * 2015-03-31 2024-02-26 Fis Fabbrica Italiana Sintetici Spa Forma sólida de agomelatina

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE457089B (sv) * 1986-02-05 1988-11-28 Sandvik Ab Saett att behandla en blandning av haardmetallkroppar foer att skilja dessa fraan varandra paa grundval av deras sammansaettningar och/eller strukturer
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
MX2009009182A (es) * 2007-02-27 2009-09-04 Vertex Pharma Co-cristales y composiciones farmaceuticas que los comprenden.

Also Published As

Publication number Publication date
CN102816079A (zh) 2012-12-12
FR2976284A1 (fr) 2012-12-14
UA112407C2 (uk) 2016-09-12
CN102816079B (zh) 2015-04-08
AP3198A (en) 2015-03-31
FR2976284B1 (fr) 2013-05-24
AP2012006308A0 (en) 2012-06-30
HK1178881A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
CO6580196A1 (es) Nuevos co- cristales de agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112013017988A2 (pt) inibidores de bace-2 para o tratamento de distúrbios metabólicos
ECSP13012770A (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
MX2015012456A (es) Compuestos heterociclicos y usos de los mismos.
CU20140081A7 (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112013031794A2 (pt) novos derivados de oxintomodulina e composição farmacêutica para o tratamento da obesidade compreendendo os mesmos
SV2008003088A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
EA201400365A1 (ru) Новые тиопроизводные лактамов в качестве высокоактивных ингибиторов hdac и их применение в качестве лекарственных средств
UA110642C2 (uk) Композиція гербіциду і сафенеру
CO7111275A2 (es) Inhibidores de dgat1 de éter cíclico de cabeza de puente
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
BR112014011254A2 (pt) 2-tiopirimidinonas
PE20151979A1 (es) Compuestos quimicos
CL2012000013A1 (es) Compuestos derivados de 4-{3-[3-(4-trifluorometil-fenil)ureido]-5-fluoro-bencilamino}-1h-pirazol-3-carboxamida; procedimiento de preparacion; composicion farmaceutica que los comprende; compuestos intermediarios; y su uso como moduladores de la actividad de las proteinas quinasa para el tratamiento del cancer.
BR112015001135A2 (pt) inibidores de histona deacetilase e composições e métodos de uso dos mesmos
CL2015000879A1 (es) Derivados de n-(2-(amina cíclicas)etil)benzamida como inhibidores p2x7.
CO7151504A2 (es) Metabolitos de (1r-trans)-n-[[2-(2,3-dihidro-4-benzofuranilo)ciclopropilo]metilo]propanamida
CU20120086A7 (es) Nuevos co-cristales de agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CY1120009T1 (el) Χρηση αγομελατινης για την ληψη φαρμακων που προοριζονται για την θεραπεια ιδεο-ψυχαναγκαστικης διαταραχης (toc)
CU20120087A7 (es) Procedimiento de síntesis y forma cristalina del hidrocloruro de 4-(3-(cis-hexahidrociclopenta(c)pirrol-2(1h)-il)propoxi)benzamida así como las composiciones farmacéuticas que la contienen
ES2403549R1 (es) Co-cristales de agomelatina con formadores de co-cristales
EA200702318A1 (ru) Применение агомелатина для получения лекарственных средств, предназначенных для лечения синдрома смита-магениса
JO3339B1 (ar) شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
CR20120109A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ECSP10010292A (es) Nuevos derivados de ácido 2-mercaptociclopentanocarboxílico, su procedimiento de preparación y las composiciones farmacéuticas que los contienen